So could you get half of that? It’s hard to say. But if we’re just picking up 10 points, that’s an incremental $100 million of revenue to our company. I like our opportunities to get in there and compete for that and ultimately have success with it.
Operator: Thank you. The next question on the line comes from Nathan Treybeck of Wells Fargo. Your line is now open.
Nathan Treybeck: Congrats on a great quarter. I don’t think I heard you specifically call out your partnership with Signify Health in your opening remarks. Can you provide an update on where you stand currently? And are you still in pilot? And when do you expect the full rollout? And also Signify just announced the CEO transition. Does this impact your outlook from this partnership? Thanks.
Quentin Blackford: Nathan, I don’t think it changes anything in terms of how we look at the partnership here I made a comment in the prepared remarks, Q1 was very encouraging. We actually signed up several new innovative primary care partners in this space. We’re excited about the collaboration with Signify. It is still in pilot phase, and we’re still working through that, but we fully expect to turn that into a broader commercial launch in the back half of this year. So a little bit early to speak to the results at this point in time. I can tell you if we see results like we saw with some of the other innovative primary care players. I point back to PCC. We saw nearly 80% of the patients that were applied patches that were asymptomatic, ultimately were found to have an arrhythmia that is very informative, and I think allows these innovative channels to really address care the way they need to.
So we’re excited by the prospects of the Signify relationship. We’re excited by the prospects of some of the other innovative primary care players that are coming into this. I think it validates our thesis that primary care is absolutely the place that this device is ultimately going to get applied into the future just with this ease of use. It’s high diagnostic yield, it’s incredible accuracy, the ability to create tremendous workflow efficiencies and ultimately, all of that comes back in play with respect to delivering incremental value and this whole focus on value-based care. I just really like the way that Zio is positioned to address this into the future. So we couldn’t be more excited, but we’re going to let that play out in the back half of the year.
And hopefully, we’re talking a whole lot more about it.
Operator: Thank you. The next question comes from David Rescott of Baird. Your line is now open.
David Rescott: Great. Thanks. And congrats on a strong start to the year here. Brice, I just wanted to clarify one comment you made then I had a question for Quentin on Signify. Did you say that the percentage of volumes that came through San Francisco exiting 2023, were above 50% or above 60%? And then on Signify, for Quentin, I appreciate the comments you just provided there. But I’m wondering if you could frame up maybe the size of the opportunity there. I think the last that the company called out was about $3 million annual in-home evaluations. Wondering if you have a sense for how many of those are kind of eligible for diagnostics, preventive services and maybe therefore, at risk for AF and then longer term and the back half of the year into 2025.
Beyond this initial rollout I’m just trying to get a sense for how this rolls in into patients? Is it more getting rolled out across these eligible patients? Or is it more offered to the patients? And therefore it’s up to the patient to decide whether or not they want to participate in some type of program like this? Thank you.
Brice Bobzien: Dave, maybe I’ll kick it off. Yes, just a clarification, just north of 60% exiting 23 with continued progress in Q1 and expected progress throughout the rest of the year.
Quentin Blackford: Yes. And I think, David, it’s early right now. I can tell you, we’ve had a lot of discussions with Signify around what the potential opportunity can look like. I think we’re still nailing that down. Probably the best way to describe it is you go back, you look at the mSToPS criteria, you look at some of the data that’s out there around identifying arrhythmias in these comorbid where other disease states are present, maybe its diabetes, maybe its COPD, maybe its obesity. It’s at least 25% or so of the population. And so if those rates apply to Signify, I think you can see that it’s a pretty significant opportunity. The question is, is there more there? We know that, that population tends to be one that needs care in the home, can’t get out to see a physician. So does that mean that it’s a little bit of a different population where those rates are even higher, we’ll see as we go.
Operator: Thank you. The next question comes from the line of Bill Plovanic from Canaccord. Please go ahead. Your line is open.
Bill Plovanic: Great, thanks. Good evening and thanks for taking my question. Just wanted to take a step back just on the launch of Zio Monitor. Just — one, you’re seeing good uptake in new accounts. Are all new accounts getting Zio Monitor and you’re still transitioning just the existing accounts? Or where are you with that? And then in terms of the compliance rate. I think one of the things you saw early on was a higher compliance rate in returning the device. And I’m wondering if that is still carrying through? Thanks.
Brice Bobzien: Bill, it’s Brice. So yes, on the rollout, that is absolutely the case. All new accounts coming on are starting with Zio Monitor. And we’re approaching, call it, that 80% or so level of existing accounts also being converted. So the progress on Zio Monitor has gone incredibly well. But you have it right with thinking all new accounts are on it, and then existing accounts will slowly come up to speed here. As far as the compliance rate, you’re absolutely right, there is a benefit to Zio monitor, much of which is related to the form factor, but frankly, also just the high diagnostic yield of the device and those coming back with data. And so we are seeing an improvement there. I will tell you, there’s a few dynamics at play here.
